Stockscreener 앱 받기
0.7696
0.70%
-0.0054
시장 영업 전:
.77
0.0004
+0.05%
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
TNYA|Tenaya Therapeutics Inc|Price:0.769|Chg%:-0.006 - TradingKey
Tenaya Therapeutics Inc (TNYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Tenaya Therapeutics, Inc. Revenue Breakdown – NASDAQ:TNYA - TradingView
Tenaya Therapeutics Inc (TNYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tenaya Therapeutics Inc|Price:0.775|Chg%:+0.002 - TradingKey
Tenaya Therapeutics Inc (TNYA) Institutional Confidence - TradingKey
Tenaya Therapeutics Q1 2026 Earnings: Slight EPS Miss as Pre-Revenue Biotech Advances Heart Disease Pipeline - dars.gov.et
Tenaya Therapeutics Inc. (TNYA) Q1 2026 Earnings: EPS Slightly Misses Estimates, Stock Declines as Pre-Revenue Biotech Continues Pipeline DevelopmentOne-Time Gain Impact - dars.gov.et
Tenaya’s new CFO gets options on 1.65M shares, with a $0.8365 exercise price - Stock Titan
Tenaya Therapeutics (TNYA) CFO files first Form 3 ownership report - Stock Titan
Tenaya Therapeutics (TNYA) grants CFO 1,650,000 stock options - Stock Titan
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Tenaya Therapeutics Inc. (TNYA) Q1 2026 Earnings: Slight EPS Miss Overshadowed by Pipeline ProgressSurprise Factor Analysis - dars.gov.et
Tenaya Therapeutics, Inc. Podcast | TNYA Podcasts & Related Content - finance.biggo.com
TNYA News | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Tenaya Therapeutics (TNYA) - The Globe and Mail
Piper Sandler reiterates Overweight on Tenaya stock, $40 target - Investing.com
TNYATenaya Therapeutics Inc Options - Finviz
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability - simplywall.st
Tenaya Therapeutics (NASDAQ: TNYA) exits Union City manufacturing lease, shifts to CDMO - Stock Titan
Tenaya Therapeutics Ends Manufacturing Center Lease, Shifts Strategy - TipRanks
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Investing News Network
Tenaya Therapeutics appoints Eric Hyllengren as CFO By Investing.com - Investing.com Australia
Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026 - marketscreener.com
Tenaya Therapeutics Appoints New Chief Financial Officer - TipRanks
Eric Hyllengren to lead finances at Tenaya Therapeutics (NASDAQ: TNYA) - Stock Titan
Tenaya Therapeutics appoints Eric Hyllengren as CFO - Investing.com
Press Release: Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Moomoo
Tenaya Therapeutics names Eric Hyllengren as ne... - Pluang
Price to book forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
Price to sales forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
Price to earnings forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
Enterprise value to revenue forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
symbol__ Stock Quote Price and Forecast - CNN
TENAYA THERAPEUTICS INC (TNYA) Stock Chart - ChartMill
Tenaya Therapeutics (TNYA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Tenaya Therapeutics Inc (TNYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tenaya Therapeutics Inc (TNYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tenaya Therapeutics Inc (TNYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tenaya Therapeutics Inc (TNYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tenaya Therapeutics Inc (TNYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tenaya Therapeutics Inc (TNYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tenaya Therapeutics Q1 2026 Earnings: EPS Slightly Misses Estimates as Biotech Advances Heart Disease Pipeline - dars.gov.et
Tenaya Therapeutics (TNYA) Q1 2026 Earnings: EPS Miss Reflects R&D Investment as Company Advances PipelineNegative Surprise Momentum - newsline.com
TNYA Q1 2026 Earnings: Slightly Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineMid-Term Outlook - newsline.com
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $2 - Moomoo
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $2 to $4 - Moomoo
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCMSlideshow (NASDAQ:TNYA) 2026-06-03 - Seeking Alpha
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in... - markets.businessinsider.com
Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms - TradingView
Tenaya reports interim data from gene therapy trial for rare heart condition - Investing.com
1.97%
0.83%
자본화:
|
볼륨(24시간):